NEW YORK, NY / ACCESSWIRE / September 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SLQT Shareholders Click Here: https://www.zlk.com/pslra-1/selectquote-inc-loss-submission-form?prid=19750&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19750&wire=1
SAM Shareholders Click Here: https://www.zlk.com/pslra-1/the-boston-beer-company-inc-loss-submission-form?prid=19750&wire=1
* ADDITIONAL INFORMATION BELOW *
Selectquote, Inc. (NYSE:SLQT)
SLQT Lawsuit on behalf of: investors who purchased February 8, 2021 - May 11, 2021
Lead Plaintiff Deadline : October 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/selectquote-inc-loss-submission-form?prid=19750&wire=1
According to the filed complaint, during the class period, Selectquote, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
SPPI Lawsuit on behalf of: investors who purchased December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline : November 1, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19750&wire=1
According to the filed complaint, during the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
The Boston Beer Company, Inc. (NYSE:SAM)
SAM Lawsuit on behalf of: investors who purchased April 22, 2021 - September 8, 2021
Lead Plaintiff Deadline : November 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-boston-beer-company-inc-loss-submission-form?prid=19750&wire=1
According to the filed complaint, during the class period, The Boston Beer Company, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Boston Beer's hard seltzer sales were decelerating; (2) as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/665028/CLASS-ACTION-UPDATE-for-SLQT-SPPI-and-SAM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
